Printer Friendly

NEW NICOTROL 'DAY PATCH' TO ENTER THE SMOKING CESSATION MARKET

 NEW NICOTROL 'DAY PATCH' TO ENTER THE SMOKING CESSATION MARKET
 MORRIS PLAINS, N.J., April 27 /PRNewswire/ -- Warner-Lambert Company (NYSE: WLA), together with Kabi Pharmacia AB and Cygnus Therapeutic Systems Inc. (NASDAQ: CYGN), announced today that approval has been received from the Food and Drug Administration to market Nicotrol (nicotine transdermal system) in the United States. Following final manufacturing validations, the product is expected to be available in pharmacies in the third quarter.
 Nicotrol -- a trademark of Kabi Pharmacia AB -- is the first nicotine transdermal system designed to be worn only during waking hours and removed at bedtime so there is no additional delivery of nicotine during sleep. The new Nicotrol "day patch" has been proven in year-long clinical testing to be a convenient and effective way for motivated individuals to stop smoking more comfortably.
 Nicotrol was co-developed by Kabi Pharmacia of Sweden, a recognized international leader in smoking cessation, and Cygnus Therapeutic Systems Inc. of California, a company known for its unique transdermal technology. The new nicotine "day patch" will be manufactured by Cygnus and marketed in the United States by Parke-Davis, a division of Warner- Lambert.
 Nicotrol (nicotine transdermal system) is a three-patch (15 mg, 10 mg and 5 mg) step-down regimen designed to help patients gradually adjust to a decreasing amount of nicotine as part of a comprehensive smoking cessation program. Although dosing regimens may vary for each patient, 16 weeks of therapy is recommended. The Nicotrol patch is an aid to smoking cessation and relieves nicotine withdrawal symptoms. The "day patch" should be used as part of a comprehensive smoking cessation behavior modification program.
 Recognizing that behavioral support is an integral part of successful smoking cessation therapy, Parke-Davis has formed a partnership with Smoke Stoppers. The program, used by approximately 350 medical centers, corporations and labor organizations including Yale New Haven Medical Center, American Airlines and the UAW-GM, is an additional aid to a comprehensive behavioral smoking cessation program. A Smoke Stoppers behavior modification kit, which includes a handbook of proven stress and weight management techniques and an audiotape of relaxation exercises, will be available to all patients prescribed Nicotrol. Additionally, a toll free information hot-line will be established, staffed by live operators and Smoke Stoppers counselors.
 Nicotrol will be the first patch to become available as an aid to smoking cessation therapy designed to be worn during waking hours only. There are currently three nicotine patches available to smokers motivated to quit that deliver nicotine continuously over 24 hours.
 "We are confident we have a winner with Nicotrol," said Joseph E. Smith, executive vice president and president, pharmaceutical sector, Warner-Lambert Company. "The combination of the research and development of Kabi Pharmacia, and the technological expertise of Cygnus, in addition to our own sales and marketing strengths, puts us in an excellent position to make the 'day patch' a success," Smith said.
 Parke-Davis, a division of Warner-Lambert Company, is devoted to research, development, manufacturing and marketing of quality health care products. Parke-Davis' principal product lines include cardiovascular, central nervous system and chemotherapy agents, including anti-cancer and anti-infective compounds, as well as female health care products.
 Kabi Pharmacia is a pharmaceutical division of Procordia AB. The company has a respected history in smoking cessation therapy and is the developer and manufacturer of Nicorette, the nicotine chewing gum, which has been marketed in the United States as a smoking cessation aid since 1984. Kabi Pharmacia holds worldwide rights to Nicotrol and will market the product outside North America.
 Cygnus is a leader in the development of advanced transdermal drug delivery systems, and has approximately 200 employees located at its Redwood City, Calif., headquarters. It has two products in advanced clinical trials, an estradiol patch for the treatment of symptoms of menopause and the prevention of osteoporosis, and a fetanyl patch for post-operative pain management. Cygnus has 11 U.S. patents issued or allowed and more than 300 patent applications worldwide covering its transdermal technology.
 -0- 4/27/92
 /CONTACT: Peter Wolf (media), 201-540-6696, or Stephen Mock or Cary Rosansky (investors), 201-540-4874, all of Warner-Lambert; Sandra Stahl of Ruder Finn, 212-593-6370, for Warner-Lambert; Carl-Johan Wachtmeister, 46-18-16-30-06, or Jorgen Johnsson, 46-42-10-43-75, both of Kabi Pharmacia in Sweden; or Shirley Clayton of Cygnus Therapeutic Systems, 415-369-4300/
 (WLA CYGN) CO: Warner-Lambert Company; Kabi Pharmacia AB; Cygnus Therapeutic
 Systems Inc. ST: New Jersey, California IN: MTC SU: PDT


GK -- NY034 -- 2998 04/27/92 09:50 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1992
Words:734
Previous Article:THE WACKENHUT CORPORATION DECLARES DIVIDEND
Next Article:KENNAMETAL DECLARES QUARTERLY DIVIDEND


Related Articles
CYGNUS SHIPS ITS NICOTINE PATCH
CYGNUS SHIPS ITS NICOTINE PATCH
PARKE-DAVIS LAUNCHES NICOTROL, FIRST NICOTINE PATCH FOR WAKING HOURS USE
WARNER-LAMBERT LAUNCHES MAJOR SMOKING CESSATION INITIATIVE; WELLNESS PROGRAM WILL ASSIST EMPLOYEES IN COPING WITH SMOKING RESTRICTIONS
WARNER-LAMBERT LAUNCHES MAJOR SMOKING CESSATION INITIATIVE; WELLNESS PROGRAM WILL ASSIST EMPLOYEES IN COPING WITH SMOKING RESTRICTIONS
NEW YEAR'S RESOLUTION SURVEY SHOWS HEALTH AS IMPORTANT GOAL FOR 1993
NEW YEAR'S RESOLUTION SURVEY SHOWS HEALTH AS IMPORTANT GOAL FOR 1993; SMOKING CESSATION A PRIORITY FOR SMOKERS AND NON-SMOKERS
DAY-TIME NICOTINE PATCH LAUNCHED WITH FREE COUNSELING SUPPORT PROGRAM
CYGNUS FILES IND FOR SECOND-GENERATION NICOTINE PATCHES
NICOTROL(R) (NICOTINE TRANSDERMAL SYSTEM) ON STORE SHELVES TOMORROW; FIRST OVER-THE-COUNTER NICOTINE PATCH NOW AVAILABLE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters